Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia
Shots:
- Juno to provide sales promotion and hospital contracting services to Australian Hospital market customers and will co-market Herzuma (biosimilar- trastuzumab) and Truxima (biosimilar- rituximab) with Celltrion in Australia
- The focus of the agreement is to market globally biosimilar brands to Australian Healthcare professionals and patients
- Herzuma (CT-P6- biosimilar- trastuzumab) is a mAb targeting the extracellular domain of HER2 receptor and has received MFDS- EC and the FDA’s approval in Jan’2014- Feb’2018 and Dec’2018 respectively. Truxima is a mAb (CT-P10- biosimilar- rituximab) is a mAb approved in Korea in 2016- EU in Feb-2017 and is a novel biosimilar approved by Health Canada for NHL- CLL and RA
Click here to read full press release/ article | Ref: Juno Pharmaceuticals | Image: Celltrion
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com